Vitamin D and Fertility: What the Research Actually Shows

Key takeaways

• Low vitamin D is sometimes associated with infertility, polycystic ovary syndrome (PCOS), miscarriage, or poorer fertility-treatment outcomes. Association does not show that low vitamin D caused the problem.
• IVF evidence is mixed. A 2023 systematic review covering 5,402 women found positive associations in 5 studies, no association in 12, and a negative association in 1; study methods were too different for the authors to pool the results (J Assist Reprod Genet, 2023).
• Small randomized trials have not established that vitamin D improves clinical pregnancy, ongoing pregnancy, embryo quality, fertilisation, miscarriage, or live birth. One signal for a positive pregnancy blood test may be a false positive because the evidence was underpowered (Frontiers in Endocrinology, 2022).
• Anti-Müllerian hormone, or AMH, estimates ovarian response and the remaining follicle pool. It does not directly measure egg quality, the chance of natural conception, or whether vitamin D will improve fertility.
• Vitamin D deficiency should be treated for health reasons when it is clinically diagnosed. Correction is not a fertility treatment, and no guideline establishes a special preconception vitamin D target that guarantees conception or IVF success.
• In pregnancy, routine vitamin D blood testing is not recommended for everyone. Standard intake and treatment of a diagnosed deficiency are different decisions, especially because high-dose products can cause harm.

The short answer

Vitamin D matters for bone and mineral health, and treating a confirmed deficiency is sensible before or during pregnancy. But research has not shown that taking vitamin D reliably increases natural conception, improves egg quality, prevents miscarriage, or raises IVF live-birth rates. It should support appropriate health care, not replace fertility evaluation or evidence-based treatment.

If you have been trying to conceive, the attraction is easy to understand. A blood test offers a number. A supplement feels actionable. Online advice then turns a biological possibility into a promise: raise the number, improve the eggs, and increase the chance of pregnancy. The real evidence is not that tidy.

Fertility depends on age, ovulation, sperm, fallopian-tube function, the uterus, timing, health conditions, and chance. Vitamin D status may sit alongside some of those factors, but a low result cannot explain infertility on its own. Nor does a higher result prove that conception will follow.

If you are planning pregnancy in Riyadh, ask your usual clinician or fertility team whether vitamin D testing is relevant to your medical history. A useful consultation should start with your history and goals, not a pre-set supplement package.

Why vitamin D became part of the fertility conversation

Vitamin D receptors and vitamin D-related enzymes have been identified in reproductive tissues. Laboratory and animal work gives researchers plausible reasons to study ovarian function, endometrial receptivity, placentation, and sperm. Plausibility, though, is the start of a research question rather than proof of a treatment.

Human studies create a second reason for interest. Low 25-hydroxyvitamin D, written as 25(OH)D, is common in many populations. It can also cluster with higher body mass index, less outdoor activity, skin pigmentation, clothing coverage, season, diet, chronic illness, and socioeconomic factors. Several of those variables are independently related to reproductive health or access to care.

That creates a problem called confounding. Imagine that people with lower vitamin D also have a higher average BMI. If one group has different pregnancy outcomes, vitamin D may be causal, BMI may explain part of the difference, or both may be markers of wider health and social patterns. Statistical adjustment helps but cannot remove every unmeasured difference.

Reverse causation can also distort the picture. Fertility treatment changes routines, medicines, hormone levels, and the timing of blood draws. A vitamin D result measured after treatment begins may not represent the person’s usual preconception status. The 2023 IVF systematic review found major differences in when 25(OH)D was measured, the thresholds used, and how pregnancy outcomes were defined (J Assist Reprod Genet, 2023).

So the biologic story is interesting. It is not enough to tell an individual that a supplement will improve fertility.

How to read fertility research without being misled

Fertility articles often place several outcomes in one sentence as if they were interchangeable. They are not.

• Biochemical or chemical pregnancy generally means that a pregnancy hormone test, such as beta-hCG, became positive.
• Clinical pregnancy usually requires ultrasound evidence of a gestational sac, sometimes with additional criteria.
• Ongoing pregnancy means the pregnancy continued beyond a study-defined point.
• Live birth means a baby was born alive. For a person considering treatment, this is usually the most meaningful endpoint.
• Implantation rate and fertilisation rate are laboratory or cycle outcomes. They do not guarantee a live birth.
• Embryo grade is a morphological assessment. It is not a direct measurement of chromosomal normality or future child health.

A trial can improve an early surrogate without changing what happens later. That is exactly why a positive beta-hCG finding cannot be advertised as an IVF success or live-birth benefit.

Study design matters too. An observational cohort can identify an association but cannot confidently establish causation. A randomized controlled trial can test an intervention more directly, but a small trial may miss a real effect or produce an unstable positive result by chance. Meta-analysis does not automatically solve these problems. Pooling several small, dissimilar trials can create a precise-looking number from fragile evidence.

The underpowered IVF literature is a useful example. In the 2022 trial-sequential meta-analysis, the accumulated sample did not reach the estimated information size required for either chemical pregnancy or clinical pregnancy. The authors estimated that 462 participants were required for the chemical-pregnancy analysis and 1,570 for clinical pregnancy, and they warned that the positive chemical-pregnancy signal could be a false positive (Frontiers in Endocrinology, 2022).

Evidence by outcome

Does vitamin D help natural conception?

There is no dependable evidence that vitamin D supplementation makes a person conceive naturally. Research in couples trying without IVF is mostly observational, and results do not line up well enough to support a treatment claim.

If pregnancy has not happened, timing matters more than chasing a nutrient number. A clinical evaluation is generally appropriate after 12 months of regular unprotected intercourse if the female partner is under 35, after 6 months if she is 35 or older, or earlier with irregular or absent periods, known endometriosis, previous pelvic infection, cancer treatment, recurrent pregnancy loss, sexual difficulties, or a known male-factor concern. These are standard decision points to discuss with a qualified clinician, not a clinic-specific pathway.

What does vitamin D mean for AMH and ovarian reserve?

AMH is often misunderstood. It is produced by cells around small ovarian follicles and is useful for estimating ovarian reserve and likely response to ovarian stimulation. It cannot count normal embryos, measure egg quality directly, or tell you whether natural conception will occur in a given month.

Age remains central because egg quantity and chromosomal quality change over time. A person can have a lower AMH and conceive naturally, or a high AMH and have difficulty conceiving for unrelated reasons. PCOS often raises AMH because there are more small follicles, which does not mean egg quality is better.

AMH can move without a meaningful change in reproductive potential. Assay variation, age, PCOS, ovarian surgery, hormonal contraception, and the clinical population all affect interpretation. Even if vitamin D altered AMH gene expression or the measured hormone, that would not prove that it created new follicles. The ovarian follicle pool is not replenished by a supplement.

Treating confirmed vitamin D deficiency may still be appropriate for bone and general health. It should not be sold as a way to improve egg quality, reverse diminished ovarian reserve, or make an AMH result “normal.”

Does vitamin D improve IVF or ICSI results?

Current evidence does not establish that vitamin D raises IVF or ICSI live-birth rates. The most honest answer is that observational results are mixed and supplementation trials are too small and heterogeneous to support a fertility promise.

The 2023 systematic review included 19 studies and 5,402 women undergoing IVF. Ten were prospective cohorts, six were retrospective cohorts, and three were clinical trials. Five studies reported a positive correlation between vitamin D status and IVF outcomes, 12 found no association, and 1 found a negative correlation. The studies differed enough that the authors did not perform a meta-analysis (J Assist Reprod Genet, 2023).

That review also shows why clinic target numbers should be treated cautiously. Studies used different cut-offs, including values below 20 ng/mL and below 30 ng/mL. Some measured serum before stimulation, others around trigger or after hormone exposure, and some studied follicular fluid. Autologous and donor-egg cycles were not always comparable. Ethnicity, BMI, embryo transfer practice, and laboratory protocols differed.

Randomized evidence is narrower. A 2022 meta-analysis of trials among women with vitamin D below 30 ng/mL found a higher rate of chemical pregnancy, with a relative risk of 1.53 and a 95% confidence interval from 1.06 to 2.20. It did not find significant effects on clinical pregnancy, good-quality embryos, fertilisation, ongoing pregnancy, or miscarriage (Frontiers in Endocrinology, 2022).

The distinction is essential. In that analysis, chemical pregnancy was defined by a beta-hCG result above a threshold 14 days after embryo transfer. A positive blood test is meaningful, but it is not the same as an ultrasound-confirmed pregnancy, an ongoing pregnancy, or a live birth.

The interventions were also very different. Trials used daily vitamin D, weekly high-dose vitamin D, calcitriol, and even a very large single dose. That prevents a clean answer about formulation, dose, duration, or safety. A research regimen is not a self-care recommendation.

The fetched evidence map found no confirmed pooled live-birth benefit. Until adequately powered trials report live birth and harms, vitamin D should not be described as an IVF add-on that improves success.

Does vitamin D help fertility in PCOS?

PCOS can involve irregular ovulation, androgen excess, polycystic ovarian morphology, insulin resistance, and higher metabolic risk. Not everyone has the same features. Vitamin D cannot diagnose PCOS, and deficiency does not explain the syndrome.

Those findings deserve study, not a treatment promise. The included trials varied in PCOS criteria, baseline vitamin D status, supplementation regimens, use of ovulation-induction medicines or assisted reproduction, and outcome quality. Some studies used co-interventions, making the effect of vitamin D harder to isolate. Pregnancy signals are not enough to establish a live-birth benefit.

For a person with PCOS who wants pregnancy, the useful questions remain practical: Are periods regular enough to suggest ovulation? Is there metabolic risk that needs assessment? How long have you been trying? Has the partner been evaluated? Are the fallopian tubes likely to be open? Which evidence-based ovulation strategy fits your circumstances?

Correcting a genuine deficiency can sit alongside that care. It does not replace it.

Can vitamin D prevent miscarriage?

No current evidence supports taking vitamin D specifically to prevent miscarriage. Some observational studies find lower vitamin D among people who experience pregnancy loss, but these studies cannot reliably tell whether low vitamin D preceded the loss, contributed to it, or simply travelled with other risk factors.

Miscarriage is common and usually is not caused by something the pregnant person did or failed to take. Chromosomal factors account for many early losses. Age, uterine factors, antiphospholipid syndrome, endocrine conditions, and other issues may matter depending on the pattern and history.

If you have repeated losses, ask for a clinical assessment rather than a nutrient-only panel. If you are bleeding or in pain now, the urgency depends on symptoms, pregnancy stage, and risk of ectopic pregnancy.

What changes once you are pregnant?

Pregnancy guidance is about maternal and fetal health, not about proving a fertility effect. The 2024 Endocrine Society guideline suggests empiric vitamin D supplementation during pregnancy because trial evidence points to possible reductions in outcomes including pre-eclampsia, preterm birth, small-for-gestational-age birth, intrauterine mortality, and neonatal mortality. The recommendation is conditional and based on low-certainty evidence (JCEM, 2024).

The same guideline suggests against routine 25(OH)D testing during pregnancy. It could not establish outcome-specific target blood concentrations. This means two ideas can both be true: standard pregnancy supplementation may be reasonable, while routine blood testing and target chasing are not supported for everyone.

The U.S. Recommended Dietary Allowance during pregnancy is 600 IU, or 15 micrograms, per day. The tolerable upper intake level for adults, including pregnancy, is 4,000 IU, or 100 micrograms, per day from all sources (NIH Office of Dietary Supplements). An upper limit is not a recommended dose, a fertility target, or proof that any amount below it is suitable for every person.

Your prenatal vitamin, separate vitamin D product, calcium product, and fortified foods can all contribute to total intake. Bring every label to a prenatal appointment. People with kidney disease, hypercalcaemia, granulomatous disease, malabsorption, bariatric surgery, or medicines that affect vitamin D metabolism need individualized advice.

Folic acid has much stronger preconception evidence for preventing neural-tube defects. The U.S. Preventive Services Task Force recommends 400 to 800 micrograms daily for people planning or capable of pregnancy, beginning at least one month before conception (USPSTF, 2023). That is a separate recommendation and should not be displaced by a focus on vitamin D.

Should you test vitamin D before trying to conceive?

Routine testing is not necessary for every healthy person trying to conceive. The 2024 Endocrine Society guideline recommends against routine 25(OH)D testing in generally healthy adults and during pregnancy, and the USPSTF concludes that evidence is insufficient to recommend screening asymptomatic adults (Endocrine Society, 2024; USPSTF, 2021).

Testing can still be appropriate when the result would change care. Saudi Council of Health Insurance criteria use an indication-based approach rather than universal screening (CHI vitamin D testing criteria).

A clinician may consider testing in the context of:

• symptoms or signs compatible with rickets or osteomalacia, such as persistent bone pain or proximal muscle weakness;
• osteoporosis, fragility fracture, or another bone-mineral disorder;
• malabsorption, inflammatory bowel disease, coeliac disease, or bariatric surgery;
• chronic kidney or liver disease;
• hyperparathyroidism, abnormal calcium, or a granulomatous condition;
• medicines that alter vitamin D metabolism;
• a previously documented deficiency, especially when response or adherence needs assessment;
• a fertility or pregnancy history in which the treating clinician has a specific medical reason to test.

Neither darker skin, indoor living, higher body weight, nor pregnancy alone automatically proves deficiency. These factors can inform a wider assessment, but current prevention guidance does not support universal testing based on them alone.

If a test is ordered, the correct test is usually serum 25(OH)D. Do not interpret one number without its units, laboratory method, clinical purpose, and medical context.

How to think about supplementation safely

There are three different situations, and blending them causes confusion.

1. Routine nutritional intake

This means meeting an age- or pregnancy-specific intake through food, fortified products, and an appropriate supplement if advised. It is not designed to push a blood result toward a fertility-clinic target.

2. Prevention in a group covered by a guideline

The 2024 Endocrine Society guideline suggests empiric supplementation during pregnancy, but the trials informing it used varying doses and did not establish a single optimal dose or target 25(OH)D concentration (JCEM, 2024). A prenatal-care clinician should reconcile this with local guidance and total intake.

3. Treatment of confirmed deficiency

Treatment may use doses above routine intake for a defined period, followed by reassessment or maintenance. The regimen depends on the severity, cause, pregnancy status, kidney and calcium health, malabsorption, medicines, adherence, and total intake. High-dose schedules used in fertility trials are not general recommendations.

Too much vitamin D can cause hypercalcaemia. Symptoms can include nausea, vomiting, muscle weakness, confusion, pain, loss of appetite, dehydration, excessive urination and thirst, and kidney stones. Severe toxicity can affect the kidneys, heart rhythm, and other organs (NIH Office of Dietary Supplements).

Check labels for duplicate vitamin D. Do not combine a prenatal vitamin, “fertility” blend, vitamin D drops, calcium product, and high-dose capsule without calculating the total. Never use a single mega-dose or a prescription-strength weekly product because it appeared in a trial or social-media post.

What about the male partner?

Male fertility contributes to many couples’ difficulty conceiving, so a female-only supplement plan can delay the right assessment. Vitamin D has been studied in relation to testosterone and semen concentration, motility, and morphology. Results are inconsistent, and a semen-parameter change is not the same as a higher pregnancy or live-birth rate.

If male-factor infertility is possible, semen analysis and a medical history are more informative than assuming vitamin D is the cause. Fever, anabolic steroid use, testosterone therapy, testicular problems, sexual dysfunction, and some occupational exposures may need direct attention.

A practical decision framework

Use this framework before spending time or money on repeated vitamin D tests or fertility supplements.

Step 1: Name the actual goal

Are you trying to support general preconception health, correct a known deficiency, understand an IVF result, manage PCOS, or investigate delayed conception? The same supplement claim cannot answer all five questions.

Step 2: Check whether fertility evaluation is due

Seek assessment based on age, time trying, cycle pattern, pregnancy-loss history, pelvic history, and partner factors. Do not postpone evaluation for several months solely to “optimize” vitamin D.

Step 3: Decide whether a test would change management

Testing is more defensible when there is a clinical indication, previous deficiency, bone disease, malabsorption, relevant medicine, or abnormal calcium-related history. If the plan would be ordinary pregnancy nutrition regardless of the result, routine testing may add cost without changing care.

Step 4: Separate deficiency care from fertility treatment

If deficiency is diagnosed, treat it because deficiency matters to health. Ask what regimen is being used, why it fits you, how total intake was calculated, whether calcium or kidney function matters, and when reassessment is needed. Do not translate correction into a promised fertility benefit.

Step 5: Protect the outcomes that matter

When reading a study or clinic claim, ask:

1. Was the study randomized?
2. How many participants were included?
3. Did it measure a blood-test pregnancy, clinical pregnancy, ongoing pregnancy, or live birth?
4. Were harms reported?
5. Did the study involve people like you?
6. Was vitamin D the only difference between groups?

If live birth is absent, the claim should not be rewritten as “IVF success.”

Step 6: Cover proven preconception basics

Discuss folic acid, medicines, vaccines, smoking or vaping, alcohol, chronic conditions, genetic or carrier screening when relevant, and partner health with a qualified clinician. Vitamin D should not crowd out higher-value care.

Frequently asked questions

The bottom line

Vitamin D belongs in preconception and pregnancy care as a nutrient, and a confirmed deficiency deserves appropriate treatment. It does not belong in fertility marketing as a promise to improve eggs, prevent miscarriage, or raise IVF live-birth rates.

If you are concerned about fertility, start with the question that changes care: is a proper fertility or preconception assessment due? If vitamin D testing is clinically indicated, interpret the result in context and treat deficiency for a defined health reason. Keep live birth separate from early surrogate outcomes, and be cautious whenever a clinic or supplement brand blurs that line.

For readers in Riyadh, Saudi Arabia, confirm appointment and testing options directly with a licensed healthcare provider. Use emergency services, not routine clinic channels, for urgent symptoms.

Related reading

• Vitamin D for women: benefits, sources, safety and evidence
• Vitamin D deficiency in women in Saudi Arabia
• Vitamin D blood test results explained
• Folate vs folic acid before and during pregnancy
• Omega-3 for women: evidence and safety

References

1. Demay MB, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907-1947. DOI: 10.1210/clinem/dgae290. Full text: https://academic.oup.com/jcem/article/109/8/1907/7685305
2. National Institutes of Health Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
3. U.S. Preventive Services Task Force. Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication. 2023. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
4. U.S. Preventive Services Task Force. Vitamin D Deficiency in Adults: Screening. 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening
5. Council of Health Insurance, Saudi Arabia. Criteria for Insurance Coverage for Vitamin D Testing. https://www.chi.gov.sa/en/aboutchi/cchiprograms/MedicineDocuments/Vitamin%20D.pdf